Halozyme Therapeutics, Inc. (HALO) Tops Q3 EPS by 9c, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $76.90 +0.92%
EPS Growth %: +17.5%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
CCEL, MHGU, PLG, More
EPS Growth %: +17.5%
Financial Fact:
Product sales: 13.33M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q3 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $22.9 million versus the consensus estimate of $19.25 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Simulations Plus (SLP) Tops Q3 EPS by 7c
- PriceSmart (PSMT) Misses Q3 EPS by 4c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
